Delta variant 60% more transmissible, reduces vaccine effect: UK experts

The latest data also indicates that over 90 per cent of new Covid-19 cases in the UK are now the Delta variant

united kingdom
Photo: Bloomberg
Press Trust of India London
4 min read Last Updated : Jun 11 2021 | 6:01 PM IST

The Delta variant of COVID-19, or the B1.617.2 variant of concern (VOC) first identified in India, is about 60 per cent more transmissible than the Alpha strain identified in the UK and also reduces the effectiveness of vaccines to some extent, UK health experts report on Friday.

Public Health England (PHE), which has been tracking VOCs on a weekly basis, said that the cases of the Delta VOC have risen by 29,892 to hit 42,323 in the country an increase of around 70 per cent.

The latest data also indicates that over 90 per cent of new COVID-19 cases in the UK are now the Delta variant, which continues to show a significantly higher rate of growth compared to the Alpha VOC which was first identified in the region of Kent in England and was the dominant variant in the country so far.

New research from PHE suggests that the Delta variant is associated with an approximately 60 per cent increased risk of household transmission compared to the Alpha variant.

Growth rates for Delta cases are high across the regions, with regional estimates for doubling time ranging from 4.5 days to 11.5 days, PHE said in its latest analysis.

There are now analyses from England and Scotland supporting a reduction in vaccine effectiveness for Delta compared to Alpha. This is more pronounced after one dose (absolute reduction in vaccine effectiveness against symptomatic infection of approximately 15 per cent to 20 per cent after one dose), its risk assessment analysis reads.

Iterated analysis continues to show vaccine effectiveness against Delta is higher after two doses but that there is a reduction for Delta compared to Alpha. There is uncertainty around the magnitude of the change in vaccine effectiveness after two doses of Oxford-AstraZeneca vaccine, it adds.

PHE said that with the Delta variant now accounting for the overwhelming majority of new cases in the UK, it is encouraging to see that the increase in cases is not yet accompanied by a similarly large increase in hospitalisations.

PHE will continue to monitor closely over the next few weeks, but the data currently suggest that the vaccination programme continues to mitigate the impact of this variant in populations who have high two dose vaccine coverage, it adds.

The health experts are using novel genotyping tests to detect the Delta VOC, giving a result for action within 48 hours. Positive tests identified through this process are subsequently confirmed through whole genome sequencing and PHE says that recent data have shown them to be extremely accurate in indicating a positive variant result.

With numbers of Delta variant cases on the rise across the country, vaccination is our best defence. If you are eligible, we urge you to come forward and be vaccinated. Remember that two doses provide significantly more protection than a single dose, said Dr Jenny Harries, Chief Executive of the UK Health Security Agency.

However, while vaccination reduces the risk of severe disease, it does not eliminate it. With data showing that Delta is significantly more transmissible than Alpha, it is just as important as ever to follow public health advice, which has not changed. Get vaccinated, work from home where you can and remember hands, face, space, fresh air' at all times. These measures work, and they save lives, she said.

The latest data comes as the UK government is set to announce its plans on Monday on whether the roadmap to lifting all lockdown restrictions by June 21 can go ahead.

There are growing voices from within the scientific community calling for a delay to that date in order to administer further second doses of vaccines for the over-50s, to ensure greater protection against the Delta variant.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jun 11 2021 | 6:00 PM IST

Next Story